One of the most critical limitations of the study was the lack of measuring other AD biomarkers in CSF, such as tau protein [88], taurine [89], beta‐amyloid, and beta‐amyloid/tau, as well as their potential impact on amino acid concentrations. This evidence concerns the gene MAPT and Alzheimer disease.